{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:30:21Z","timestamp":1787020221083,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T00:00:00Z","timestamp":1458000000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2271-8","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T11:12:37Z","timestamp":1458299557000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors"],"prefix":"10.1186","volume":"16","author":[{"given":"Ko","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Ohtsubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Okajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junta","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Sakagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Koya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kagamu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,15]]},"reference":[{"issue":"21","key":"2271_CR1","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","volume":"26","author":"JP Pignon","year":"2008","unstructured":"Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552\u20139.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2271_CR2","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/jnci\/djk196","volume":"99","author":"A Ardizzoni","year":"2007","unstructured":"Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99(11):847\u201357.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2271_CR3","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ctrv.2012.09.006","volume":"39","author":"A Rossi","year":"2013","unstructured":"Rossi A, Martelli O, Di Maio M. Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice. Cancer Treat Rev. 2013;39(5):498\u2013506.","journal-title":"Cancer Treat Rev"},{"issue":"14","key":"2271_CR4","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma. J Clin Oncol. 2003;21(14):2636\u201344.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2271_CR5","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00204-012-0821-7","volume":"86","author":"NA Santos dos","year":"2012","unstructured":"dos Santos NA, Carvalho Rodrigues MA, Martins NM, dos Santos AC. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol. 2012;86(8):1233\u201350.","journal-title":"Arch Toxicol"},{"issue":"2","key":"2271_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/sj.ki.5002017","volume":"71","author":"K Yamagata","year":"2007","unstructured":"Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, Narita M, Koyama A. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71(2):159\u201366.","journal-title":"Kidney Int"},{"key":"2271_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.1","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1\u2013138.","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"2271_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/ki.2008.107","volume":"74","author":"CY Hsu","year":"2008","unstructured":"Hsu CY, Ordo\u00f1ez JD, Chertow GM, Fan D, McCulloch CE, Go AS. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int. 2008;74(1):101\u20137.","journal-title":"Kidney Int"},{"issue":"9","key":"2271_CR9","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/cncr.28509","volume":"120","author":"BK Edwards","year":"2014","unstructured":"Edwards BK, Noone A-M, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, Jemal A, Cho H, Anderson RN, Kohler BA, et al. Annual Report to the Nation on the status of cancer, 1975\u20132010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120(9):1290\u2013314.","journal-title":"Cancer"},{"issue":"6","key":"2271_CR10","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982\u201392.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2271_CR11","doi-asserted-by":"publisher","first-page":"R204","DOI":"10.1186\/cc2872","volume":"8","author":"R Bellomo","year":"2004","unstructured":"Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204\u201312.","journal-title":"Crit Care"},{"key":"2271_CR12","unstructured":"Common Terminology Criteria for Adverse Events v4.0 (CTCAE). 6\/2010 update. Available at: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40 . Accessed 15 Mar 2016."},{"issue":"7","key":"2271_CR13","first-page":"633","volume":"16","author":"PK Li","year":"2011","unstructured":"Li PK, Chow KM, Matsuo S, Yang CW, Jha V, Becker G, Chen N, Sharma SK, Chittinandana A, Chowdhury S, et al. Asian chronic kidney disease best practice recommendations: positional statements for early detection of chronic kidney disease from Asian Forum for Chronic Kidney Disease Initiatives (AFCKDI). Nephrology (Carlton). 2011;16(7):633\u201341.","journal-title":"Nephrology (Carlton)"},{"issue":"6","key":"2271_CR14","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649\u201355.","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"2271_CR15","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1183\/09031936.00055110","volume":"37","author":"C Mathe","year":"2010","unstructured":"Mathe C, Bohacs A, Duffek L, Lukacsovits J, Komlosi ZI, Szondy K, Horvath I, Muller V, Losonczy G. Cisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patients. Eur Respir J. 2010;37(4):888\u201394.","journal-title":"Eur Respir J"},{"issue":"5","key":"2271_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"9804","key":"2271_CR17","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/S0140-6736(10)62101-0","volume":"378","author":"P Goldstraw","year":"2011","unstructured":"Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, Shepherd FA. Non-small-cell lung cancer. Lancet. 2011;378(9804):1727\u201340.","journal-title":"Lancet"},{"issue":"9804","key":"2271_CR18","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(11)60165-7","volume":"378","author":"JP Meerbeeck van","year":"2011","unstructured":"van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011;378(9804):1741\u201355.","journal-title":"Lancet"},{"issue":"9","key":"2271_CR19","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.ejca.2005.01.024","volume":"41","author":"DG Warr","year":"2005","unstructured":"Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, Wit R, Carides AD, Taylor A, Evans JK, Horgan KJ. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer. 2005;41(9):1278\u201385.","journal-title":"Eur J Cancer"},{"issue":"9","key":"2271_CR20","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1007\/s00520-013-1835-2","volume":"21","author":"S Miura","year":"2013","unstructured":"Miura S, Watanabe S, Sato K, Makino M, Kobayashi O, Miyao H, Iwashima A, Okajima M, Tanaka J, Tanaka H, et al. The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013;21(9):2575\u201381.","journal-title":"Support Care Cancer"},{"issue":"7","key":"2271_CR21","doi-asserted-by":"publisher","first-page":"e101902","DOI":"10.1371\/journal.pone.0101902","volume":"9","author":"Y Kidera","year":"2014","unstructured":"Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, Kaneda H, Nishina S, Tsurutani J, Fujiwara K, et al. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS ONE. 2014;9(7):e101902.","journal-title":"PLoS ONE"},{"issue":"6","key":"2271_CR22","first-page":"562","volume":"4","author":"K Muraki","year":"2012","unstructured":"Muraki K, Koyama R, Honma Y, Yagishita S, Shukuya T, Ohashi R, Takahashi F, Kido K, Iwakami S, Sasaki S, et al. Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer. J Thorac Dis. 2012;4(6):562\u20138.","journal-title":"J Thorac Dis"},{"issue":"6","key":"2271_CR23","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/j.1875-9114.1997.tb03088.x","volume":"17","author":"JL Lagrange","year":"1997","unstructured":"Lagrange JL, Medecin B, Etienne MC, Pivot X, Cassuto-Viguier E, Renee N, Thyss A, Ferrero JM, Otto J, Francois E, et al. Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factors. Pharmacotherapy. 1997;17(6):1246\u201353.","journal-title":"Pharmacotherapy"},{"issue":"7","key":"2271_CR24","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/ki.2008.350","volume":"74","author":"LG Fine","year":"2008","unstructured":"Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int. 2008;74(7):867\u201372.","journal-title":"Kidney Int"},{"issue":"9","key":"2271_CR25","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/sj.ki.5002786","volume":"73","author":"N Pabla","year":"2008","unstructured":"Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994\u20131007.","journal-title":"Kidney Int"},{"issue":"4","key":"2271_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s002800050661","volume":"40","author":"DJ Stewart","year":"1997","unstructured":"Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, Goel R. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol. 1997;40(4):293\u2013308.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"2271_CR27","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/cncr.22904","volume":"110","author":"V Launay-Vacher","year":"2007","unstructured":"Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, Morere J-F, Beuzeboc P, Deray G. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management. Cancer. 2007;110(6):1376\u201384.","journal-title":"Cancer"},{"issue":"2","key":"2271_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000168693","volume":"14","author":"G Brillet","year":"1994","unstructured":"Brillet G, Deray G, Jacquiaud C, Mignot L, Bunker D, Meillet D, Raymond F, Jacobs C. Long-term renal effect of cisplatin in man. Am J Nephrol. 1994;14(2):81\u20134.","journal-title":"Am J Nephrol"},{"issue":"30","key":"2271_CR29","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.3748\/wjg.v17.i30.3510","volume":"17","author":"HH Moon","year":"2011","unstructured":"Moon HH. Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients. World J Gastroenterol. 2011;17(30):3510.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"2271_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nrneph.2012.280","volume":"9","author":"KCW Leung","year":"2012","unstructured":"Leung KCW, Tonelli M, James MT. Chronic kidney disease following acute kidney injury\u2014risk and outcomes. Nat Rev Nephrol. 2012;9(2):77\u201385.","journal-title":"Nat Rev Nephrol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2271-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-016-2271-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2271-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2271-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T23:05:10Z","timestamp":1718406310000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2271-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,15]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2271"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2271-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,15]]},"article-number":"222"}}